{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:14:57Z","timestamp":1791346497336,"version":"4.3.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:47:28Z","timestamp":1786492048000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral gene replication enhances AAV vector quality and reduces manufacturing costs"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-409X","authenticated-orcid":false,"given":"Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiupeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-2360","authenticated-orcid":false,"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.008_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.008_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib3","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.008_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.canlet.2014.10.045","article-title":"Adeno-associated virus-mediated cancer gene therapy: current status","volume":"356","author":"Luo","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2026.08.008_bib6","first-page":"482","article-title":"Clinical trials in neurological disorders using AAV vectors: promises and challenges","volume":"6","author":"Mandel","year":"2004","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102725","article-title":"Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases","volume":"11","author":"Li","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2026.08.008_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/v17020239","article-title":"Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy","volume":"17","author":"Zwi-Dantsis","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2026.08.008_bib9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.ymthe.2025.12.067","article-title":"Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies","volume":"34","author":"Duan","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2131\/jts.46.57","article-title":"Development challenges associated with rAAV-based gene therapies","volume":"46","author":"Bolt","year":"2021","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.008_bib11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101230","article-title":"Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection","volume":"32","author":"Liu","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.18609\/cgti.2019.175","article-title":"Cost modelling comparison of adherent multi-trays with suspension and fixed-bed bioreactors for the manufacturing of gene therapy products","volume":"5","author":"Cameau","year":"2019","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.ymthe.2026.08.008_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/gt.2010.27","article-title":"Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors","volume":"17","author":"Zeltner","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107764","article-title":"Cellular pathways of recombinant adeno-associated virus production for gene therapy","volume":"49","author":"Sha","year":"2021","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2026.08.008_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2005.02.008","article-title":"Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production","volume":"335","author":"Li","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2026.08.008_bib17","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Suarez-Amaran","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.omtm.2017.12.004","article-title":"Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes","volume":"9","author":"Nass","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.omtm.2021.03.016","article-title":"Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9","volume":"21","author":"Joshi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib21","first-page":"169","article-title":"A clinician's guide to AAV production - How manufacturing platforms shape vector properties","volume":"37","author":"Magnus","year":"2025","journal-title":"Med. Genet."},{"key":"10.1016\/j.ymthe.2026.08.008_bib22","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.008_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-025-04073-z","article-title":"Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy","volume":"32","author":"Buddle","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.008_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0092-8674(81)90282-8","article-title":"SV40-transformed simian cells support the replication of early SV40 mutants","volume":"23","author":"Gluzman","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.008_bib25","article-title":"Large T antigen mediated target gene replication improves site-specific recombination efficiency","volume":"12","author":"Wang","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/nar\/20.2.245","article-title":"High level transient gene expression in human lymphoid cells by SV40 large T antigen boost","volume":"20","author":"de Chasseval","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.008_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/330272a0","article-title":"Elevated c-myc expression facilitates the replication of SV40 DNA in human lymphoma cells","volume":"330","author":"Classon","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.008_bib28","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a013003","article-title":"Adenovirus DNA replication","volume":"5","author":"Hoeben","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006013","article-title":"Genome-Wide Estimation of the Spontaneous Mutation Rate of Human Adenovirus 5 by High-Fidelity Deep Sequencing","volume":"12","author":"Risso-Ballester","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2026.08.008_bib30","first-page":"187","article-title":"Adenovirus DNA replication: protein priming, jumping back and the role of the DNA binding protein DBP","volume":"272","author":"de Jong","year":"2003","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/sj.gt.3302088","article-title":"High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells","volume":"10","author":"Gao","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071032","article-title":"Canine adenovirus type 2 vector generation via I-Sce1-mediated intracellular genome release","volume":"8","author":"Ibanes","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.08.008_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101582","article-title":"Genome-replicating HC-AdV: A novel high-capacity adenoviral vector class featuring enhanced in situ payload expression","volume":"33","author":"Kolibius","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib34","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1101\/gad.12.24.3831","article-title":"Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations","volume":"12","author":"Richardson","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib35","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ymthe.2020.06.021","article-title":"Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice","volume":"28","author":"Lahey","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/hgtb.2016.188","article-title":"Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities","volume":"28","author":"Schn\u00f6dt","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2026.08.008_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70179","article-title":"Engineering of High-Yield Recombinant Adeno-Associated Virus Producer Plasmids","volume":"21","author":"Radukic","year":"2026","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ymthe.2026.08.008_bib38","first-page":"1","article-title":"Adeno-associated virus biology","volume":"807","author":"Weitzman","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.71.2.1079-1088.1997","article-title":"The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection","volume":"71","author":"Pereira","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib40","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1128\/jvi.68.5.2947-2957.1994","article-title":"Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels","volume":"68","author":"Ky\u00f6sti\u00f6","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib41","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/jvi.69.9.5485-5496.1995","article-title":"Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters","volume":"69","author":"H\u00f6rer","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.08.008_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/v12060662","article-title":"The Interplay between Adeno-Associated Virus and its Helper Viruses","volume":"12","author":"Meier","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2026.08.008_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","article-title":"Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment","volume":"2","author":"Wright","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2026.08.008_bib45","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1089\/hum.2019.249","article-title":"Rescue of Adeno-Associated Virus Production by shRNA Cotransfection","volume":"31","author":"Guimaro","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.virol.2008.11.038","article-title":"SV40 DNA replication: from the A gene to a nanomachine","volume":"384","author":"Fanning","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2026.08.008_bib47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1089\/hum.1995.6.10-1329","article-title":"Cell lines for the production of recombinant adeno-associated virus","volume":"6","author":"Clark","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib48","first-page":"1124","article-title":"A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors","volume":"3","author":"Clark","year":"1996","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib49","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1089\/hum.1998.9.16-2353","article-title":"High-titer adeno-associated viral vectors from a Rep\/Cap cell line and hybrid shuttle virus","volume":"9","author":"Gao","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/mthe.2000.0132","article-title":"Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines","volume":"2","author":"Liu","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/1521-2254(200007\/08)2:4<260::AID-JGM111>3.0.CO;2-8","article-title":"Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome","volume":"2","author":"Chadeuf","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2026.08.008_bib52","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41467-022-28738-2","article-title":"Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination","volume":"13","author":"Su","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.008_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/v15010064","article-title":"High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector","volume":"15","author":"Weger","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2026.08.008_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101370","article-title":"Characterization of the function of Adenovirus L4 gene products and their impact on AAV vector production","volume":"32","author":"Nie","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.08.008_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.008_bib56","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s44321-025-00248-w","article-title":"High-purity AAV vector production utilizing recombination-dependent minicircle formation and genetic coupling","volume":"17","author":"Liu","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2026.08.008_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102563","article-title":"AAVone: A cost-effective, single-plasmid solution for efficient AAV production with reduced DNA impurities","volume":"36","author":"Yang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.08.008_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.854690","article-title":"Rescue of Recombinant Adenoviruses by CRISPR\/Cas-Mediated in vivo Terminal Resolution","volume":"13","author":"Riedl","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib59","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/JVI.03120-15","article-title":"A Regulatory Element Near the 3' End of the Adeno-Associated Virus rep Gene Inhibits Adenovirus Replication in cis by Means of p40 Promoter-Associated Short Transcripts","volume":"90","author":"Weger","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib60","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1021\/acssynbio.2c00207","article-title":"Construction of an rAAV Producer Cell Line through Synthetic Biology","volume":"11","author":"Lee","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.ymthe.2026.08.008_bib61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bit.28562","article-title":"Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization","volume":"121","author":"Lu","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ymthe.2026.08.008_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202400051","article-title":"Tuning capsid formation dynamics in recombinant adeno-associated virus producing synthetic cell lines to enhance full particle productivity","volume":"19","author":"Lu","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ymthe.2026.08.008_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2024.109552","article-title":"Development of inducible packaging cell line for rAAV production via CRISPR-Cas9 mediated site-specific integration","volume":"213","author":"Fu","year":"2025","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.ymthe.2026.08.008_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.70009","article-title":"A synthetic platform for developing recombinant adeno-associated virus type 8 producer cell lines","volume":"41","author":"Lin","year":"2025","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ymthe.2026.08.008_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2026.110144","article-title":"Development of an inducible stable producer cell line for rAAV production","volume":"230","author":"Fu","year":"2026","journal-title":"Biochem. Eng. J."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:28:44Z","timestamp":1787390924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626006891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"alternative-id":["S1525001626006891"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.008","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral gene replication enhances AAV vector quality and reduces manufacturing costs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}